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avoided versus ENOX’ was quantiﬁed using a modelling
approach based on decision-tree technique synthesising pub-
lished data and a hospital survey. Safety and efﬁcacy values of
VTE prevention with the comparators were taken from the
EPHESUS [Lassen et al. Lancet 2002], PENTAMAKS [Bauer
et al. NEJM 2001] and PENTHIFRA [Eriksson et al. NEJM
2001] trials. Data on resource utilization (staff, drugs, materials,
laboratory, and equipment) during thromboprophylaxis, diagno-
sis and treatment came from the hospital survey. Resources were
valued in internal hospital prices as of the ﬁrst quarter of 2007.
The evaluation exclusively encompassed inpatient days for
thromboprophylaxis and treatment of VTE and major bleed
during the MOSLL-related hospital stay. RESULTS: In the base-
case analysis, FOND dominated ENOX: cost savings of €3430
were obtained and 11.8 clinical VTE were avoided by FOND
versus ENOX, each per 1000 patients. In comprehensive sensi-
tivity analyses, using impact analysis and Monte Carlo simula-
tion, the robustness of these results was tested. The rate of
prophylaxis-related bleeding with FOND (RPBF) had the great-
est impact on the savings. FOND remained cost-saving in 61%
and 77% of 10,000 iterations with the ﬁrst FOND injection 6
hours after surgical closure (RPBF = 0.028) or the morning after
surgery (RPBF = 0.019), respectively. FOND remained more
effective than ENOX without exception: after 10,000 iterations,
between 4.6 and 21.2 clinical VTE were avoided by FOND
versus ENOX per 1000 patients. CONCLUSION: FOND offers
hospitals in Germany a clinically and economically advantageous
alternative for prevention and treatment of VTE in patients
undergoing MOSLL.
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OBJECTIVES: To evaluate the long-term outcomes of serolimus-
eluting stents (SES) in comparison to bare-metal stents (BMS)
in elective treatment of coronary artery disease (CAD).
METHODS: In the prospectiveGERSHWIN study in 35 hospitals
in Germany, CAD patients undergoing percutaneous coronary
intervention (PCI) were electively treated with SES or BMS
(sequential control design with a case : control ratio of 2 : 1).
Standardized questionnaires completed by patients and physicians
at 3, 6, 12, and 18 months following PCI documented major
adverse coronary events (MACE), including death, myocardial
infarct, coronary bypass surgery and re-PCI in target vessel (TVR),
as well as disease-related direct and indirect costs. RESULTS:
From April 2003 until June 2005, 658 patients were treated with
SES (87% male, mean age 63  9) und 294 patients with BMS
(79%male, mean age 64  10). After 18 months, 13% of the SES
cohort and 20% of the BMS cohort had suffered a MACE (p
adjusted < 0.01). Initial hospital costs were signiﬁcantly higher
for SES than for BMS (6001  57 vs. 3913  69 EUR, p
adjusted < 0.01) and the respective 18-month follow-up direct
and indirect costs were similar (7949  462 vs. 8360  554 EUR
p adjusted = 0.455). Over 18 months, total TVR-related and
disease-related costs were higher in SES compared to BMS:
12,876  438 vs. 11,501  525 EUR and 13,950  468 vs.
12,273  562 EUR, respectively, both p adjusted < 0,01. For
TVR costs, the cost-effectiveness of SES was 15,995 EUR per
patient free from MACE and for total disease-related costs,
19,500 EUR. CONCLUSION: In comparison to patients follow-
ing BMS implantation, patients 18 months following implanta-
tion of SES experienced signiﬁcantly fewer MACE. The higher
initial costs for SES compare to BMS were followed by similar
economic consequences in both groups with cost-effectiveness of
under 20,000 EUR per patient free from MACE.
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OBJECTIVES: To evaluate the cost-effectiveness of serolimus-
eluting stents (SES) to bare-metal stents (BMS) in patients with
single-vessel coronary artery disease (SVD) compared with
patients with multi-vessel disease (MVD). METHODS: In the
prospective GERSHWIN study in 35 hospitals in Germany,
patients with coronary artery disease (CAD) undergoing percu-
taneous coronary intervention (PCI) were electively treated with
SES or BMS (sequential control design). Standardized question-
naires completed by patients and physicians through 18 months
following PCI documented major adverse coronary events
(MACE), including death, myocardial infarction, coronary artery
bypass surgery and re-PCI in target vessel, as well as disease-
related direct and indirect costs. RESULTS: From April 2003
until June 2005, 658 patients were treated with SES (87% male,
mean age 63  9) und 294 patients with BMS (79% male, mean
age 64  10). SVD was documented in 34% BMS patients and
29% SES patients. After 18 months, 8% of SES and 25% of BMS
patients with SVD had suffered MACE in comparison to 15% of
SES and 19% of BMS patients with MVD, indicating a difference
in the effect of SES with respect to the underlying CAD status (p
adjusted = 0.023). In SVD, SES and BMS incurred total costs of
EUR 11,832 and 12,399, respectively. In MVD, SES and BMS
incurred total costs of EUR 14,964 and 12,026, respectively (p
adjusted = 0.003). In patients with SVD, the cost-effectiveness of
SES was EUR 12,805 per patient free from MACE compared to
EUR 16,488 in BMS. In patients with MVD, the cost-
effectiveness of SES was EUR 17,522 per patient free from
MACE compared to EUR 14,810 in BMS. CONCLUSION: In
patients with SVD, SES is more cost effective than BMS whereas
in patients with MVD, SES is less cost effective than BMS.
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OBJECTIVES: The purpose of this study was to evaluate the
relative cost-effectiveness (cost-utility) of the angiotensin II
antagonist eprosartan versus other antihypertensives (nitren-
dipine, perindopril, enalapril) in a secondary prevention setting
(hypertensives with cerebrovascular disease at baseline) in
Belgium, Germany, Spain, UK and Sweden. METHODS: The
HEALTH model (Health Economic Assessment of Life with
Teveten® for Hypertension) is an object-oriented probabilistic
Monte Carlo simulation model. It combines a Framingham-
based risk calculation with a systolic blood pressure approach to
estimate the relative risk reduction of cardiovascular and cere-
brovascular events based on recent meta-analyses. For eprosar-
tan an additional risk reduction was modelled according to the
results of the MOSES study (‘Morbidity and Mortality after
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